Promising phase 2 results for biodexa's erapa(tm) indicates hope for fap patients who otherwise have a 100% lifetime risk of colorectal cancer

Cardiff, uk / accesswire / june 3, 2024 / biodexa pharmaceuticals (nasdaq:bdrx) just announced promising phase 2 results for its newly in-licensed drug erapa for treating familial adenomatous polyposis (fap), a mainly genetic disease of the lower gi tract for which there is currently no remedy except surgical removal of the colon and/or rectum. in a clinical trial involving 30 adult patients, three groups received the same dose of the drug but with different regimens over a period of 12 months.
BDRX Ratings Summary
BDRX Quant Ranking